1 Article

The Feasibility of Studying Metabolites in PICU 2

Multi-Organ Dysfunction Syndrome Patients Over 3

an 8-day Course Using An Untargeted Approach 4

5 Mara L. Leimanis-Laurens, PhD^{1,2*}, Danny Gil, MD^{1,2*}, Andrew Kampfshulte, MS³, Claire

6 Krohn, MD(2021)⁴, Elizabeth Prentice, DO^{1,2}, Dominic Sanfilippo, MD^{1,2}, Jeremy W. Prokop,

7 PhD^{2,5}, Todd Lydic, PhD⁶, Surender Rajasekaran, MD, MPH^{1,2,3}

- 8 ¹Pediatric Critical Care Unit, Helen DeVos Children's Hospital, 100 Michigan Street NE, Grand Rapids, MI, 9 49503
- 10 ²Department of Pediatrics and Human Development, College of Human Medicine, Michigan State
- 11 University, Life Sciences Building, 1355 Bogue Street, East Lansing, MI, 48824
- 12 ³Spectrum Health, 100 Michigan Street NE, Grand Rapids, MI, 49503
- 13 ⁴Michigan State University, College of Human Medicine, 15 Michigan Street NE, Grand Rapids, MI, 49503
- 14 ⁵Department of Pharmacology and Toxicology, Michigan State University, 1355 Bogue Street, East Lansing, 15 MI, 48824, United States
- 16 ⁶Department of Physiology, Collaborative Mass Spectrometry Core, 578 S. Shaw Ln. Chemistry
- 17 Building, Michigan State University, East Lansing, MI 48824
- 18
- 19 *Authors contributed equally to this work
- 20 *Correspondence: E-mail: mara.leimanis@spectrumhealth.org; Tel.: (+1 616-267-0106)
- 21 Received: date; Accepted: date; Published: date

22 Abstract: Metabolites are generated from critical biological functions and metabolism. This 23 pediatric study reviewed plasma metabolites in patients suffering from multi-organ dysfunction 24 syndrome (MODS) in the pediatric intensive care unit (PICU) using an untargeted metabolomics 25 approach. Patients meeting criteria for MODS were screened for eligibility and consented (n=24), 26 and blood samples were collected at baseline, 72 hours, and 8 days; control patients (n=4), were 27 presenting for routine sedation in an outpatient setting. A sub-set of MODS patients (n=8) required 28 additional support with veno-atrial extracorporeal membrane oxygenation (VA-ECMO) therapy. 29 Metabolites from thawed blood plasma were determined from ion pairing reversed-phase LC-MS 30 analysis. Chromatographic peak alignment, identification, relative quantitation, statistical and 31 bioinformatics evaluation were performed using MAVEN and MetaboAnalyst 4.0. Metabolite 32 analysis revealed 115 peaks per sample. From the PLS-DA with VIP scores above \geq 2.0, 7 dynamic 33 metabolites emerged over the 3 time points: tauro-chenodeoxycholic acid (TCDCA), hexose, p-34 hydroxybenzoate, hydroxyphenylacetic acid (HPLA), 2_3-dihydroxybenzoic acid, 2-keto-35 isovalerate, and deoxyribose phosphate. After Bonferonni adjustment for repeated measures 36 hexose and *p*-hydroxybenzoate were significant at one time point, or more. Kendall's tau-b test 37 was used for internal validation of creatinine. Metabolites may be benign or significant in 38 describing a patient's pathophysiology and require operator interpretation.

39 Keywords: blood plasma, extracorporeal membrane oxygenation, metabolites, multiple organ 40 dysfunction syndrome, pediatric intensive care unit, liquid chromatography mass spectrometry

41 1. Introduction

42 The ability to identify, quantify, and analyze the metabolic profile of a pediatric patient, allows 43 us to investigate the interaction between both physiologic and pathologic states. Metabolites are 44 under the control of environmental pressures, such as nutrition [1], viral infections (such as Covid-NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. 19 [2], Ebola [3]), gut bacterial composition and cancer [4], medications [5,6], and a patient's own pre-45 46 existing genetic make-up [7]. Metabolites, being low molecular weight molecules and/or products

perpetuity. All rights reserved. No reuse allowed without permission.

of metabolic pathways, are growing in appeal medically over the last decade for their potential indisease characterization, drug discovery and precision medicine [8,9].

49 We have previously described the current cohort of patients for patient whole blood 50 transcriptomics [10,11], and plasma lipidome [12]. This has revealed a complex biology in a 51 heterogenous patient population with a non-uniform patient response to treatments over an 8-day 52 course (stabilization and recovery phases) of illness during a PICU admission. Complimentary to 53 these previously reported analytic modalities from whole blood [10-12], the aim of this current report 54 was two-fold: 1) to characterize total blood plasma metabolites (polar, charged) using an untargeted 55 approach, 2) to determine change in metabolites over an 8-day PICU course. There is a gap in our 56 understanding of the complex interaction between pediatric critical illness, specifically multi-organ 57 dysfunction syndrome (MODS) [13] (affecting twenty percent of PICU admissions [14], resulting in 58 ten times the mortality rate [15]), and their respective blood metabolites.

59 2. Materials and Methods

60 2.1 Study Population, Site and Sample Collection

61 After IRB approval, a short-term longitudinal design was adopted at Helen DeVos Children's 62 Hospital (2016-062-SH/HDVCH). Samples were collected under the protocol and study design [10-63 12] in a quaternary-care, urban, pediatric hospital in Western, Michigan. In brief, patients who were 64 identified as having MODS were enrolled, 24 in total, with an additional 4 sedation-control patients. 65 These 24 patients were then further classified as needing veno-arterial extracorporeal membrane 66 oxygenation (VA-ECMO) as a therapeutic modality (n=8) according to Extracorporeal Life Support 67 Organization (ELSO) criteria [16]. Blood samples from the patients were obtained and placed into 68 EDTA-filled tubes, plasma was processed and stored at -80 ° C for later use. All samples had 69 undergone one freeze-thaw before processing and analysis.

- 70
- 71

2.2 Metabolite Extraction and Liquid Chromatography-Mass Spectrometry (LC-MS)

72

73 samples (~50 microliters) were subjected to biphasic Plasma extraction using 74 chloroform/methanol/water as described previously [17] to remove nonpolar matrix interferences 75 and recover polar metabolites in the aqueous extraction phase. Stable isotope labeled (D⁴)-succinate 76 was added to plasma during extraction for use in estimation of metabolite recovery and for relative 77 quantitation across experimental groups. Samples were filtered through 0.2 micron syringe filters 78 (Fisher Scientific) and reconstituted in 100 microliters of 50 % methanol for use in ion pairing 79 reversed-phase LC-MS analysis.

80 Targeted polar metabolite identification utilized a Thermo Scientific model TSQ Vantage triple 81 quadrupole mass spectrometer operating in negative ion mode. The mass spectrometer was 82 coupled to a Shimadzu Prominence HPLC with thermostated column oven and autosampler. Ten 83 microliter sample injections were subjected to gradient elution with (A) 10 mM tributylamine and 15 84 mM acetic acid (pH 4.95), and (B) Methanol according to B. Luo, et al. [18], with separation of 85 metabolites achieved on a Phenomenex Synergi Hydro-RP C18 column (2.0 mm x 150 mm, 3 micron 86 particles, 80 Angstrom pore size). The column was protected by a Phenomenex guard cartridge of 87 identical chemistry. Metabolites were identified and quantitated by selected ion monitoring. 88 Detection parameters for each precursor/product ion pair of interest have been optimized based 89 using commercially available standards.

- 90
- 91 2.3 Data analysis92

LC-MS data analysis of chromatographic peak alignment, compound identification, relative
 quantitation, and statistical evaluation across experimental groups will be performed using MAVEN
 software [19]. Only relative quantitation of analytes against a selected internal standard was
 performed for comparison of values across experimental treatment groups. "Absolute" quantitation

perpetuity. All rights reserved. No reuse allowed without permission.

was not carried out in these experiments. Metabolites as listed in Supplemental Table 1, were
initially categorized as anabolic vs. catabolic and endogenous vs. exogenous according to Human
Metabolite Data Base (HMDB) (https://hmdb.ca/metabolites/) (Supplemental Figure 1).

100 Metabolic profiles for sedation-controls were compared to MODS or ECMO patients, quantified 101 as percent of total. Metabolites with >30% of cases with zero values were excluded from further 102 analysis; consequently 66 metabolites were analyzed over the three time points (Figure 1). Using 103 MetaboAnalyst 4.0 [20], data were normalized using pareto scaling (mean-centered and divided by 104 the square root of standard deviation of each variable), and subjected to a multi-variate partial least 105 squares-discriminant analysis (PLS-DA) analysis [21], using Q2 values for cross-validation [22]. No 106 data points were excluded. To assess the significance of class discrimination, a permutation test was 107 performed and PLS-DA model built [between the data (X) and the permuted class labels (Y)] using 108 the optimal number of components as determined by cross validation for the model based on the 109 original class assignment [23]. This guided analysis allowed for the display of each specific group 110 assignment. Variable Importance in Projection (VIP) is a weighted sum of squares of the PLS 111 loadings considering the amount of explained Y-variation in each dimension.

112 Univariate analysis was performed using MedCalc (MedCalc Software Ltd, Ostend, Belgium) 113 for candidate metabolites as determined by variance of importance (VIP) scores >2.0 from seven 114 metabolites, using independent T-tests (equal variances), and Welch-test (unequal variances). A 115 Bonferroni correction of P-value (<0.008) was used to identify statistically significant associations 116 with metabolites (to control for Type I errors), which was calculated by dividing the significance 117 threshold of 0.05 by the number of repeated measures; in this case MODS and ECMO compared to 118 sedation-controls (at baseline, time 72hrs and 8 days). Box and whisker plots were generated for the 119 two remaining metabolites of interest, which included the median, the interquartile range (box), the 120 outer range (whiskers) to pictorially summarize the central tendency, dispersion, skewness, and 121 extremes of the dataset [24].

122 **3. Results**

123 3.1 Metabolite Ontology and Origin

All 115 metabolites are listed in Supplemental Table 1 according to compound identification from the metabolic mass to charge ratio and retention time. From here we looked at the ontology of the metabolites in order to characterize according to any known function and origin. We found that the majority of metabolites detected were endogenous in nature (76%), and associated with catabolic (38%), anabolic (35%), both catabolic and anabolic metabolism (14%), or unspecified mechanisms of action (13%) (Supplement Figure 1 A & B), according to HMDB (<u>https://hmdb.ca/metabolites/</u>).

130

131 3.2 Bioinformatic Analysis

Analytical flow chart is presented in Figure 1. Percent total of metabolites and change over time
were visualized using supervised analysis PLS-DA, which revealed clustering of ECMO patients
within the MODS patients over the three time points, as compared to the sedation-control group
(Figure 2, A, B, C). These groupings were also visualized by heatmap analysis (Supplemental Figure
2, A, B, C), supporting the initial finding of the PLS-DA, whereby the sedation-control patients were
found to cluster amongst themselves.

139

All rights reserved. No reuse allowed without permission.

4 of 10





Figure 2: PLS-DA plot of all patient samples at baseline (A), 72 hours (B), and 8 days (C)



145 146

140

141 142 143

144

Figure 2: Insert: PLS-DA classification using different number of components. The red star indicates the best classier.

147 148

149 The important features as identifies by the PLS-DA at baseline (Figure 3A), at 72 hours (Figure 150 3B) and at 8 days (Figure 3C), reveal seven metabolites with relative concentrations of the 151 corresponding metabolite in each group under study. In total seven metabolites of interest emerged 152 tauro-chenodeoxycholic acid (TCDCA)-a conjugated bile acid, hexoseover the 3 time points: 153 monosaccharide-simple sugar, p-hydroxybenzoate-biocide-antimicrobial agent/tyrosine, tryptophan, 154 phenylalanine metabolite, hydroxyphenylacetic acid (HPLA)-metabolite of phenylalanine, 2 3-155 dihydroxybenzoic acid-drug metabolite, 2-keto-isovalerate-cellular intermediate for the synthesis of 156 branched-chain amino acids, deoxyribose phosphate-a pentose phosphate.

157 Starting with HPLA (with a VIP score \geq 1.5 at 8 days) over the 3-time points, sedation-control 158 values are consistently highest, with ECMO patients demonstrating an intermediate profile and 159 MODS patients with the lowest values according to the relative concentrations. 2_3-160 dihydroxybenzoic acid and deoxyribose-phosphate share similar relative concentration profiles to 161 HPLA with the values highest for sedation-control patients compared to MODS with the lowest 162 relative concentrations.

163 In the exact opposite profile is hexose, which reveals the highest relative concentrations values 164 in MODS patients as compared to sedation-controls, again with ECMO sharing intermediate profiles 165 at baseline. By day 8 however, this has changed completely, whereby sedation-controls have the 166 highest relative concentrations, and ECMO the lowest, with MODS demonstrating intermediate 167 profiles. We may extrapolate from this that the patients with critical illness demonstrate some 168 fluctuations in hexose over time, and that the detection of this blood plasma metabolite is a dynamic 169 process. Patients were neither hyper- nor hypo-glycemic according to their clinical glucose levels 170 (also a 6-carbon sugar-data not shown), and this is closely monitored at the PICU bedside, given blood

All rights reserved. No reuse allowed without permission.

5 of 10

glucose levels have been previously demonstrated to adversely affect patient outcomes, especially inthe case of hyperglycemia [25].

173 Remaining metabolites of interest include *p*-hydroxybenzoate with exception of the 72 hours' 174 time point, reveal that ECMO patients have lower relative concentrations than MODS patients, and 175 TCDCA, which is consistently lower in sedation-control patients, as compared to both MODS and 176 ECMO. TCDCA is a maker of liver injury, which is still elevated after 8 days for MODS and ECMO 177 patients. It is believed that shock liver common in this patient population usually subsides after a 178 few days, from our results we may speculate that this metabolite is still present at the 8th day post-179 Lastly, keto-isovalerate like hexose and TCDCA has higher relative study enrollment. 180 concentrations for both MODS and ECMO patients compared to sedation-controls at both baseline 181 and 72 hours (at 8-days similar patterning, however VIP score <1.0). Additional metabolites of note 182 include lactate (VIP score ≥ 1.5) which would be expected in this group of patients [24], which is 183 highest in ECMO patients, second in MODS and lowest in the sedation-controls at the 72-hour time 184 point.

- 185
- 185

187

Figure 3: Important features identified by PLS-DA at baseline (A), 72 hours (B), and 8 days (C).




Figure 3: The colored boxes on the right indicate the relative concentrations of the corresponding
 metabolite in each group under study. TCDCA: tauro-chenodeoxycholic acid.

190

192

191 3.3 Repeated Measures Over 3 Time Points

Furthermore, it was of interest to determine whether any of those metabolites identified by PLS-DA with high VIP scores where statistically significant over time, as this may provide additional understanding and potential biomarker identification of this cohort of untargeted metabolites. When comparing to sedation-controls and correcting for Bonferonni adjustment for repeated measures (P-value <0.008), both hexose and p-hydroxybenzoate were significant at, at least one time point (Table 1).

199

All rights reserved. No reuse allowed without permission.

200

- 201
- 202

203

Table 1: Repeated measures summary statistics for VIP ≥ 2.0 at baseline (A), 72 hours (B), and 8 days (C).


Metabolites	Hydroxyphenylacetic acid				2_3_dihydroxybenzoic acid				2-keto-isovalerate				Deoxyribose phosphate				Hexose				p-hydroxybenzoate				TCDCA			
	Mean	SD	Median	P-value	Mean	SD	Median	P-value	Mean	SD	Median	P-value	Mean	SD	Median	P-value	Mean	SD	Median	P-value	Mean	SD	Median	P-value	Mean	SD	Median	P-value
Sedation (n=4)	47.40	53.93	44.87		16.00	10.56	13.58		6.52	0.97	6.63		6.79	4.60	6.71		15.80	3.26	14.37		53.12	7.66	53.00		0.22	0.323	0.08	
40DS BL (n=16	1.82	5.29	0.43	P = 0.1900	1.81	2.63	0.74	P = 0.0760	11.83	8.64	10.03	P = 0.0291	1.09	1.12	0.73	P = 0.0907	37.22	24.03	30.55	P = 0.0031"	65.01	36.71	56.51	P = 0.2476	2.53	4.14	0.77	P = 0.04
ECMO BL (n=8)	4.72	10.12	0.81	P = 0.2146	10.98	14.87	4.80	P = 0.5631	9.33	3.91	9.41	P = 0.0879	2.25	3.25	1.15	P = 0.0733	21.03	19.43	23.88	P = 0.4799	26.59	20.68	15.73	P = 0.3170	14.30	25.76	2.53	P = 0.16
10DS 72h (n=15	6.94	12.2	2.39	P = 0.2331	2.10	3.15	1.23	P = 0.0804	10.60	5.07	8.18	P = 0.0127	0.79	0.65	0.62	P = 0.0802	9.79	12.38	0.19	P = 0.1228	19.16	15.29	13.74	P = 0.0251	11.87	24.91	1.93	P = 0.10
ECMO 72h (n=7)	7.87	7.65	6.7	P = 0.2410	5.12	4.39	4.32	P = 0.0366	9.78	4.33	7.91	P = 0.0981	1.40	0.77	1.31	P = 0.1025	2.94	6.76	0.10	P = 0.0065	41.73	20.51	39.74	P = 0.0482	9.20	9.10	4.95	P = 0.04
MODS 8d (n=8)	24.04	19.50	20.97	P = 0.4629	2.54	1.85	1.38	P = 0.0855	14.04	6.96	11.71	P = 0.0172	0.53	0.57	0.27	P = 0.0729	2.77	7.46	0.14	P = 0.0083	24.57	23.82	14.20	P = 0.0021	792.38	2208	8.05	P = 0.34
ECMO 8d (n=6)	13.66	12.16	10.70	P = 0.3062	4.68	7.96	1.45	P = 0.0878	9.70	5.10	7.87	P = 0.1874	0.77	0.34	0.68	P = 0.0793	0.08	0.03	0.07	P = 0.0024	9.05	3.047	9.20	P < 0.0001	6.66	7.604	4.15	P = 0.09

204	Table 1. Independent T-test performed (assuming equal variances); *F-test for equal variances was P
205	= < 0.05 Welch-test (assuming unequal variances) was used; P-values less than 0.008 were deemed
206	significant, after the Bonferonni adjustment; comparing MODS and ECMO samples to sedation-
207	controls; TCDCA: tauro-chenodeoxycholic acid.

Box and whisker-plots were generated to be able to visualize the distribution of samples over time (Figure 4). From this we can visualize a large spread of patient blood plasma metabolite values, and that the values change over the three time points. More frequent and intensive sampling would be necessary to determine exact distribution for the acute, stabilization and recovery phases of MODS and ECMO patients, using a metabolic platform. This illustrates the complexity and the dynamic nature of sampling for this patient population.

214 215

Figure 4: Top two metabolites with significant differences from sedation-controls over 8-days.



216

Figure 4: Box and whisker plots, which include the median, the interquartile range (box), the outer range (whiskers) and pictorially summarize the central tendency, dispersion, skewness, and extremes of the dataset using a linear scale. MODS: multi-organ dysfunction syndrome; ECMO: extracorporeal membrane oxygenation; BL: baseline; 72: 72-hour time point; 8D: 8-day time point. Stars denote statistical significance from Independent T-test, or Welch-test as compared to sedation-controls.

223 3.4 Internal Validation

Kendall's tau-b test was used for internal validation, and revealed a positive correlation between creatinine and the respective creatinine metabolite at all three time points (baseline: τb=0.708, p=0.000; Phours: τb=0.511, p=0.001; 8 days: 0.684, p=0.001) (Supplemental Figure 3). While the three coefficients yielded similar results, the skewness and heteroskedasticity of the data violate the assumptions for Pearson's r. Spearman's Rho and Kendall's Tau are both non-parametric and

All rights reserved. No reuse allowed without permission.

acceptable to use in this case. Spearman's Rho measures the rank correlation (how the ranks of the x and y values align), and Kendall's Tau measures the percent of concordant pairs, which is also based on ranks but considered to be a more robust measure. Creatinine was found to be high at baseline, which correlated with clinical creatinine values.

233 4. Discussion

Untargeted analyses are intended to provide a means for finding differences in abundance across samples or groups of samples. Multivariate statistical techniques are therefore well suited to analysis of untargeted metabolomics data. MetaboAnalyst is a web-based platform created and developed by the Wishart group from the University of Alberta, offering R-based software for public use [20,26], and was the software of choice for this analysis.

From these preliminary results we may glean a few main findings: 1) metabolites of MODS and ECMO patients contain both Phase I and Phase II metabolites; 2) are dynamic in nature; 3) contain both potentially clinically relevant findings (such as TCDCA), as well as those of benign (±inert) function, as normally metabolized and excreted through downstream organ systems (renal, digestive); 4) metabolites can be measured and qualified in blood plasma of critically ill pediatric patients using an untargeted approach, which correlated to clinical values for routine care (e.g. creatinine).

Phase I and Phase II metabolites were detected amongst the 66 values analyzed. Recent evidence suggests that gut microbiome influences blood metabolites [27], which undergo Phase I metabolism through oxidation (R-OH), reduction (R-SH), or hydrolysis (R-NH₂), and Phase II metabolism through sulfation (R-SO₃H), glucuronidation (R-Gluc) and glutathione conjugation (R-Gl). This may suggest that there are greater metabolic influences beyond the scope this this study that need to be controlled for in future work, such as including gut microbiome profiles.

252 *p*-hydroxybenzoate, is thought to be produced via two major pathways: 1) microbial oxidation 253 of petroleum derivative toluene into *p*-hydroxybenzoate, as described for *Pseudomonas* species [28]; 254 and 2) the *de novo* bioproduction of *p*-hydroxybenzoate from amino acids (tyrosine, tryptophan, 255 phenylalanine) through and intermediate chorismite, via the enzyme chorismite lyase (UbiC) [29]. 256 *p*-hydroxybenzoate (paraben and alkyl ester derivative) is commercially used as a preservative and 257 antimicrobial agent pharmaceutical and cosmetic industry [30], and therefore may be from an 258 exogenous source. The second possibility is an endogenous source, which has been described in 259 Escherichia coli [31] and Mycobacterium tuberculosis [32], as produced from glucose, and can be toxic at 260 higher-concentrations. Lower levels of *p*-hydroxybenzoate as observed in our MODS and ECMO 261 patients at day 8 is a Phase I metabolite, and may be an indication of a gut bacteria dysbiosis (impaired 262 microbiota), and to date has not been described in this patient population.

263 The most dynamic metabolite described herein is hexose which reflects the fluctuating energetic 264 state of the patients. Low hexose at the third time point (8 days-post MODS diagnosis and into their 265 PICU admission) could be a sign of energy deficiency, however we know that the patients were under 266 close monitoring and by 72 hours were all receiving some nutritional intervention [12], after largely 267 being *nil per os* at baseline. Blood glucose control has been further evaluated in Covid-19 patients, 268and is of ongoing concern given reports of higher mortality and multi-organ injury [33]. HPLA, a 269 phenylcarboxylic acid, has been speculated to be a marker of sepsis in adult cardiac surgery, however 270 requires further validation [34].

Cholesterol breaks down in the liver to produce primary bile acids, one being chenodeoxycholic acid, which together with taurocholic acid produces a conjugated bile acid TCDCA and excreted in the intestine, constituting our enterohepatic circulation. In spite of normalizing liver enzymes (alanine transaminase (ALT) Aspartate transaminase (AST)) in this patient population as previously reported [11], TCDCA remained elevated as compared to sedation-controls at the 8-day time point. This indicates that the metabolic profile may illustrate a different landscape on patient recovery, and metabolites may be organ specific.

Limitations of the work include a low sample volume, capturing high-abundance metabolites,and sample integrity may have been compromised by a previous freeze-thaw cycle. A second cohort

All rights reserved. No reuse allowed without permission.

8 of 10

study would be necessary for further metabolite identification and validation to explore their clinicalutility.

282 5. Conclusions

It is feasible to measure blood plasma metabolites in pediatric patients with MODS and undergoing ECMO treatment. Metabolites may be benign or significant in describing a patient's pathophysiology, fluctuate over time and require operator interpretation.

- 286 6. Abbreviations
- 287
- 288 HPLA: hyroxyphenylacetic acid: LC-MS: Liquid chromatography-mass spectrometry; MODS: multi-
- 289 organ dysfunction syndrome; PICU: pediatric intensive care unit; PLS-DA: partial least squares-
- 290 discriminant analysis; VA-ECMO: veno-atrial extracorporeal membrane oxygenation; VIP: variance
- 291 of importance; TCDCA: tauro-chenodeoxycholic acid.

Supplementary Materials: Table S1: Metabolites identified n=115, metMz-mass over charge ratio, metRt-retention time, compound name, and compound ID listed; Figure S1: a) Metabolic actions of 115 metabolites identified; b) Ontological sources of 115 metabolites identified, taken from Human Metabolite Data Base (HMDB) (https://hmdb.ca/metabolites/); Figure S2: Clustering result shown as heatmaps at baseline (A), 72 hours (B), and 8 days (C); Figure S3: Correlation of clinical creatinine to untargeted metabolite value(s).

Author Contributions: SR, DG and ML conceived of the original study design, screened, recruited, and collected
 all samples. Sample processing, peak findings, annotation, and quantification for metabolites was performed by
 TL. ML and AK performed all statistical and bioinformatic analysis. CK contributed to the annotation of
 individual metabolites. SR, DG, ML, AK, CK, BP, DS, JP and TL all contributed to the writing and editing of
 the manuscript.

Funding: Funding for this project was provided for SR, ML by Spectrum Health Office of Research (SHOR)
 funding initiative for precision medicine (#R51100431217), Helen DeVos Children's Hospital Foundation
 (HDVCH), grant (#R51100881018), and HDVCH Foundation grant (DG, SR, ML). NIH Office of the Director
 and NIEHS grant K01ES025435 (JWP).

Acknowledgments: The authors would like to thank the PICU staff at HDVCH for their support in the
 completion of this study and various contributions. Dr. David Tack and Dr. Alan Davis, for their additional
 statistical support.

309 Conflicts of Interest: The authors declare no conflict of interest. The funders had no role in the design of the 310 study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to 311 publish the results.

312 References

- Leimanis Laurens, M.L.; Kraus-Friedberg, C.; Kar, W.; Sanfilippo, D.; Rajasekaran, S.; Comstock, S.S.
 Dietary Intake Influences Metabolites in Infants: A Scoping Review. *Nutrients* 2020, *12*, 2073.
- Shen, B.; Yi, X.; Sun, Y.; Bi, X.; Du, J.; Zhang, C.; Quan, S.; Zhang, F.; Sun, R.; Qian, L., et al. Proteomic
 and Metabolomic Characterization of COVID-19 Patient Sera. *Cell* 2020, *182*, 59-72.e15,
 doi:10.1016/j.cell.2020.05.032.
- Kyle, J.E.; Burnum-Johnson, K.E.; Wendler, J.P.; Eisfeld, A.J.; Halfmann, P.J.; Watanabe, T.; Sahr, F.;
 Smith, R.D.; Kawaoka, Y.; Waters, K.M., et al. Plasma lipidome reveals critical illness and recovery from
- 320 human Ebola virus disease. *Proc Natl Acad Sci U S A* **2019**, *116*, 3919-3928, doi:10.1073/pnas.1815356116.
- Louis, P.; Hold, G.L.; Flint, H.J. The gut microbiota, bacterial metabolites and colorectal cancer. *Nature reviews. Microbiology* 2014, *12*, 661-672, doi:10.1038/nrmicro3344.

All rights reserved. No reuse allowed without permission.

- Lai, F.Y.; Erratico, C.; Kinyua, J.; Mueller, J.F.; Covaci, A.; van Nuijs, A.L. Liquid chromatography quadrupole time-of-flight mass spectrometry for screening in vitro drug metabolites in humans:
 investigation on seven phenethylamine-based designer drugs. *Journal of pharmaceutical and biomedical analysis* 2015, 114, 355-375, doi:10.1016/j.jpba.2015.06.016.
 Reed, G.A. Stability of Drugs, Drug Candidates, and Metabolites in Blood and Plasma. *Current protocols*
- 327 6. Reed, G.A. Stability of Drugs, Drug Candidates, and Metabolites in Blood and Plasma. *Current protocols* 328 *in pharmacology* 2016, 75, 7.6.1-7.6.12, doi:10.1002/cpph.16.
- Shin, S.Y.; Fauman, E.B.; Petersen, A.K.; Krumsiek, J.; Santos, R.; Huang, J.; Arnold, M.; Erte, I.; Forgetta,
 V.; Yang, T.P., et al. An atlas of genetic influences on human blood metabolites. *Nature genetics* 2014, 46,
 543-550, doi:10.1038/ng.2982.
- Beger, R.D.; Dunn, W.; Schmidt, M.A.; Gross, S.S.; Kirwan, J.A.; Cascante, M.; Brennan, L.; Wishart,
 D.S.; Oresic, M.; Hankemeier, T., et al. Metabolomics enables precision medicine: "A White Paper,
 Community Perspective". *Metabolomics* 2016, *12*, 149, doi:10.1007/s11306-016-1094-6.
- Wishart, D.S. Emerging applications of metabolomics in drug discovery and precision medicine. *Nature reviews. Drug discovery* 2016, *15*, 473-484, doi:10.1038/nrd.2016.32.
- Prokop, J.W.; Shankar, R.; Gupta, R.; Leimanis, M.L.; Nedveck, D.; Uhl, K.; Chen, B.; Hartog, N.L.; Van
 Veen, J.; Sisco, J.S., et al. Virus-induced genetics revealed by multidimensional precision medicine
 transcriptional workflow applicable to COVID-19. *Physiological genomics* 2020, 52, 255-268,
 doi:10.1152/physiolgenomics.00045.2020.
- Shankar, R.; Leimanis, M.L.; Newbury, P.A.; Liu, K.; Xing, J.; Nedveck, D.; Kort, E.J.; Prokop, J.W.; Zhou,
 G.; Bachmann, A.S., et al. Gene expression signatures identify paediatric patients with multiple organ
 dysfunction who require advanced life support in the intensive care unit. *EBioMedicine* 2020, 62, 103122,
 doi:https://doi.org/10.1016/j.ebiom.2020.103122.
- Leimanis-Laurens, M.L.; Ferguson, K.; Wolfrum, E.; Boville, B.; Sanfilippo, D.; Lydic, T.; Prokop, J.;
 Rajasekaran, S. Pediatric Multi-Organ Dysfunction Syndrome: Analysis by an Untargeted Shotgun
 Lipidomic Approach Reveals Low-abundance Plasma Phospholipids and Dynamic Recovery Over 8Day Period, a Single-Center Observational Study. *medRxiv* 2020, 10.1101/2020.11.24.20237891,
 2020.2011.2024.20237891, doi:10.1101/2020.11.24.20237891.
- Proulx, F.; Fayon, M.; Farrell, C.A.; Lacroix, J.; Gauthier, M. Epidemiology of sepsis and multiple organ
 dysfunction syndrome in children. *Chest* 1996, 109, 1033-1037, doi:10.1378/chest.109.4.1033.
- Typpo, K.V.; Petersen, N.J.; Hallman, D.M.; Markovitz, B.P.; Mariscalco, M.M. Day 1 multiple organ
 dysfunction syndrome is associated with poor functional outcome and mortality in the pediatric
 intensive care unit. *Pediatr Crit Care Med* 2009, *10*, 562-570, doi:10.1097/PCC.0b013e3181a64be1.
- 355 15. Typpo, K.; Watson, R.S.; Bennett, T.D.; Farris, R.W.D.; Spaeder, M.C.; Petersen, N.J.; Pediatric Existing 356 Data Analysis, I.; Pediatric Acute Lung, I.; Sepsis Investigators, N. Outcomes of Day 1 Multiple Organ 357 Dysfunction Syndrome in the PICU. Pediatr Crit Care Med 2019, 20, 914-922, 358 doi:10.1097/PCC.00000000002044.
- 35916.Brain, M.J.; Butt, W.W.; MacLaren, G. Physiology of Extracorporeal Life Support (ECLS). In360Extracorporeal Life Support for Adults. , G., S., Ed. Humana Press, New York, NY.: 2016; Vol. 16, pp. 1-60.
- 361 17. Busik, J.V.; Reid, G.E.; Lydic, T.A. Global analysis of retina lipids by complementary precursor ion and
 362 neutral loss mode tandem mass spectrometry. *Methods Mol Biol* 2009, 579, 33-70, doi:10.1007/978-1 363 60761-322-0_3.
- 36418.Luo, B.; Groenke, K.; Takors, R.; Wandrey, C.; Oldiges, M. Simultaneous determination of multiple365intracellular metabolites in glycolysis, pentose phosphate pathway and tricarboxylic acid cycle by

366		liquid chromatography-mass spectrometry. J Chromatogr A 2007 , 1147, 153-164,
367		doi:10.1016/j.chroma.2007.02.034.
368	19.	Clasquin, M.F.; Melamud, E.; Rabinowitz, J.D. LC-MS data processing with MAVEN: a metabolomic
369		analysis and visualization engine. Curr Protoc Bioinformatics 2012 , Chapter 14, Unit14 11,
370		doi:10.1002/0471250953.bi1411s37.
371	20.	Chong, J.; Wishart, D.S.; Xia, J. Using MetaboAnalyst 4.0 for Comprehensive and Integrative
372		Metabolomics Data Analysis. <i>Curr Protoc Bioinformatics</i> 2019 , <i>68</i> , e86, doi:10.1002/cpbi.86.
373	21.	Mevik, BH.; Wehrens, R. The pls Package: Principal Component and Partial Least Squares Regression
374		in R. Journal of Statistical Software 2007 , 18, doi: <u>http://dx.doi.org/10.18637/jss.v018.i02</u> .
375	22.	Kuhn, M. caret: Classication and Regression Training. Williams., C.f.J.W.a.S.W.a.A., Ed. 2008.
376	23.	Bijlsma, S.; Bobeldijk, I.; Verheij, E.R.; Ramaker, R.; Kochhar, S.; Macdonald, I.A.; van Ommen, B.;
377		Smilde, A.K. Large-Scale Human Metabolomics Studies: A Strategy for Data (Pre-) Processing and
378		Validation. Analytical Chemistry 2006 , 78, 567-574, doi:10.1021/ac051495j.
379	24.	Banacos, P.C. Box and whisker plots for local climate datasets interpretation and creation using Excel
380		2007/2010. U.S. Department of Commerce, National Oceanic and Atmospheric Administration, National
381		Weather Service] 2011 .
382	25.	Patki, V.K.; Chougule, S.B. Hyperglycemia in critically ill children. Indian J Crit Care Med 2014, 18, 8-13,
383		doi:10.4103/0972-5229.125427.
384	26.	Chong, J.; Soufan, O.; Li, C.; Caraus, I.; Li, S.; Bourque, G.; Wishart, D.S.; Xia, J. MetaboAnalyst 4.0:
385		towards more transparent and integrative metabolomics analysis. Nucleic Acids Research 2018, 46, W486-
386		W494, doi:10.1093/nar/gky310.
387	27.	Wikoff, W.R.; Anfora, A.T.; Liu, J.; Schultz, P.G.; Lesley, S.A.; Peters, E.C.; Siuzdak, G. Metabolomics
388		analysis reveals large effects of gut microflora on mammalian blood metabolites. Proc Natl Acad Sci U S
389		A 2009 , <i>106</i> , 3698-3703, doi:10.1073/pnas.0812874106.
390	28.	S. Miller Jr, E.; W. Peretti, S. Bioconversion of toluene to p-hydroxybenzoate . via the construction and
391		characterization of a recombinant Pseudomonas putida. Green Chemistry 1999, 1, 143-152,
392		doi:10.1039/A901383K.
393	29.	Verhoef, S.; Ruijssenaars, H.J.; de Bont, J.A.M.; Wery, J. Bioproduction of p-hydroxybenzoate from
394		renewable feedstock by solvent-tolerant Pseudomonas putida S12. Journal of Biotechnology 2007, 132, 49-
395		56, doi: <u>https://doi.org/10.1016/j.jbiotec.2007.08.031</u> .
396	30.	Lindsey, A.S.; Jeskey, H. The Kolbe-Schmitt Reaction. Chemical Reviews 1957, 57, 583-620,
397		doi:10.1021/cr50016a001.
398	31.	Barker, J.L.; Frost, J.W. Microbial synthesis of p-hydroxybenzoic acid from glucose. Biotechnology and
399		Bioengineering 2001 , 76, 376-390, doi: <u>https://doi.org/10.1002/bit.10160</u> .
400	32.	Stadthagen, G.; Korduláková, J.; Griffin, R.; Constant, P.; Bottová, I.; Barilone, N.; Gicquel, B.; Daffé, M.;
401		Jackson, M. p-Hydroxybenzoic Acid Synthesis in Mycobacterium tuberculosis. Journal of Biological
402		Chemistry 2005 , 280, 40699-40706, doi:10.1074/jbc.M508332200.
403	33.	Zhu, L.; She, Z.G.; Cheng, X.; Qin, J.J.; Zhang, X.J.; Cai, J.; Lei, F.; Wang, H.; Xie, J.; Wang, W., et al.
404		Association of Blood Glucose Control and Outcomes in Patients with COVID-19 and Pre-existing Type
405		2 Diabetes. Cell Metab 2020 , 31, 1068-1077.e1063, doi:10.1016/j.cmet.2020.04.021.
406	34.	Beloborodova, N.V.; Khodakova, A.S.; Olenin, A.J. Are phenylcarboxylic acids really markers in severe
407		sepsis? Critical Care 2009, 13, P41-P41, doi:10.1186/cc8097.
408		